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57 ABSTRACT 
A composition comprising nerve growth factor and 
2-amino-1,1,3-tricyano-1-propene useful for the induc 
tion, stimulation, and maintenance of nerve growth, and 
methods of potentiating choline O-acetyltransferase and 
tyrosine hydroxylase by 2-amino-1,1,3-tricyano-1-pro 
pene are disclosed. 
11 Claims, No Drawings 
5,194,426 
1. 
METHOD FOR NERVE GROWTH INDUCTION 
This is a division of application Ser. No. 253,167 filed 
Oct. 4, 1988, now U.S. Pat. No. 5,023,238. 
INTRODUCTION 
The present invention relates to nerve growth induc 
tion, stimulation, and maintenance, and enzyme potenti 
ation. More particularly, the present invention relates to 
2-amino-1,1,3-tricyano-1-propene and a method of in 
ducing, stimulating, and maintaining nerve growth 
therewith, and methods of potentiating choline-O- 
10 
a composition comprising nerve growth factor and 
acetyltransferase and tyrosine hydroxylase by means of 15 
2-amino-1,1,3-tricyano-1-propene. 
BACKGROUND OF THE INVENTION 
Nerve growth plays a major role in the development 
of host nervous systems, as well as the survival and 
regeneration of component nerve cells subject to dam 
age or destruction by injury or disease, such as cogni 
tive disorders associated with dementia. 
20 
Nerve growth factor, a polypeptide, induces nerve 
growth in hosts (for reviews on nerve growth factor, 
see L. A. Green and E. M. Shooter, Ann. Rev. Neu 
rosci., 3, 353 (1980) and B. A. Yanker and E. M. 
Shooter, Ann. Rev. Biochem, 51, 845 (1982)). 2 
Amino-1,1,3-tricyano-1-propene, a dimer of malnoni 
trile, also promotes nerve growth in host systems (see, 
for example, R. T. Houlihan and J. P. DaVanzo, Exper 
imental Neurology, 10, 183 (1964). It has now been 
found that nerve growth factor in combination with 
2-amino-1,1,3-tricyano-1-propene synergistically 
duces, stimulates, and maintains nerve growth, thereby 
rendering the cornbination more effective than either 
component in restoring nerve function diminished by 
injuries or degenerative conditions, e.g., Alzheimer's 
disease (see F. Hefti and W. J. Weiner, Annals of Neu 
rology, 20, 275 (1986). 
Cholinergic and adrenergic defects are also impli 
cated in nerve degenerative disorders (see, for example, 
K.L. Davis and R. C. Mohs, The New England Journal 
of Medicine, 315, 1286 (1986). It has now also been 
found that 2-amino-1,1,3-tricyano-1-propene potentiates 
choline-O-acetyltransferse and tyrosine hydroxylase, 
thereby augmenting its nerve growth restorative prop 
erties and usefulness in nerve degenerative conditions 
including, e.g., Parkinson's disease, S. H. Appel, Ann. 
Neurol, 10,499 (1981). 
DESCRIPTION OF THE INVENTION 






prising nerve growth factor and 2-amino-1,1,3-tricyano 
1-propene useful for the induction, stimulation, and 55 
maintenance of nerve growth in hosts. The present 
invention also relates to the potentiation of choline-O- 
acetyltransferase and tyrosine hydroxylase by 2-amino 
1,1,3-tricyano-1-propene. 
As used throughout the specification and appended 
claims, the phase "inducing nerve growth' refers to the 
production of nerve cells from non-neuritic cells; the 
phrase "stimulating nerve growth" refers to the en 
2 
hanced production of nerve cells from neuritic cells; the 
phrase "maintaining nerve growth" refers to the protec 
tion or continuing existence of nerve cells; the term 
"potentiating' refers to the enhancement of the effects 
of an agent by another agent so that the total effect is 
greater than the sum of the effects of either agent; the 
expression "cholinergic nerves' refers to nerves which 
liberate acetylcholine at a synapse; and the expression 
"adrenergic nerves ' refers to nerves which liberate 
catecholamines. 
2-Amino-1,1,3-tricyano-1-propene is prepared by the 
methods described in U.S. Pat. No. 2,719,861, issued 
Oct. 4, 1955. 
Nerve growth factor is isolated by the processes re 
ported in S. Varon, et al., Biochem, 6, 2202 (1967). 
Included among nerve growth factors are those derived 
from fish, reptiles, avaian species, and mammals such as 
mice and rabbits. The male mouse submaxillary gland is 
a particularly abundant source of nerve growth factor. 
Administration of a composition of nerve growth 
factor and 2-amino-1,1,3-tricyano-1-propene to a host, a 
mammal, for example, a mouse or a rabbit induces, 
stimulates, and maintains nerve growth within nervous 
systems. Among nervous systems there may be men 
tioned the central, peripheral, and autonomic nervous 
systems. Representative nerves of the central nervous 
systems are cholinergic and adrenergic nerves; repre 
sentative nerves of the peripheral nervous system are 
the sciatic, ulnar, radials, and median nerves; and repre 
sentative nerves of the autonamic nervous system are 
the vagus, facial, glosso-pharyngeal, and spanchnic 
nerves. 
The nerve growth induction, stimulation, and mainte 
nance effects of the composition of nerve growth factor 
and 2-amino-1,1,3-tricyano-1-propene are demonstrated 
as follows: 
Rat adrenal pheochromcytoma (PC-12) cells (com 
mercially available and on deposit in the American 
Type Culture Collection (Deposit No. ATCC CRL 
1721)) are maintained in Dulbecco's modified eagles 
media-high glucose (DMEM-H) with 5% fetal calf 
serum and 5% horse serum. PC-12 cells (5x10), 
counted by means of a hemacytometer, are plated in 25 
mils of (DMEM-H) in 75 cm2 untreated plastic flasks 
(Costar) and kept in an atmosphere of 7.5% carbon 
dioxide at 37' C. PC-12 cells are fed every 3-4 days by 
decantation of the media and the addition of fresh me 
dia, and the cultures are split every week. PC-12 cells 
(1-5x10 cells per well) are plated in 96-well tissue 
culture plates and diluted in concentrations of nerve 
growth factor, 2-amino-1,1,3-tricyano-1-propene, 2 
amino-1,1,3-tricyano-1-propene and nerve growth fac 
tor, and media without additives. Neutrite outgrowth 
was determined, after 24, 48, and 72 hours, by counting 
the percentage of cells with neurites that are twice the 
cell body length relative to the total number of cells. 
Potentiation and synergism experiments are carried out 
with constant concentrations of 2-amino-1,1,3-tricyano 
1-propene and various nerve growth factor concentra 
tions over a range of 0.1 ng/ml to 100 ng/ml (subthresh 
old to maximum). Neurite outgrowth is determined as 
above. 
Compound or Composition Peak Conc 
RESULTS 
Count (% of cells) 




Compound or Composition Peak Conc Count (% of cells) 
2-amino-1,1,3-tricyano 
1-propene 
nerve growth factor 
2-amino-1,1,3-tricyano 
1-propene 









20 ug/ml G 48 hr 
0.1 ng/ml G 48 hr 
132 pg/ml G 48 hr 
G 0.1 ng/ml 
G 132 pg/ml 
G 0.1 ng/ml 
G 20 ug/ml 
} G 48 hr 







Nerve growth induction, stimulation, and mainte 
nance are achieved when the compositions are adminis 
tered to a subject requiring such treatment as an effec 
tive oral. parenteral, intracerebral, or intravenous dose 
of from about 15 to about 45 ug/kg of body weight per 
day. A particularly preferred effective amount is about 
20 ug/kg of body weight per day. It is to be understood, 
however, that for any particular subject, specific dosage 
regimens should be adjusted to the individual need and 
the professional judgment of the person administering 
or supervising the administration of the aforesaid com 
positions. It is to be further understood that the dosages 
set forth herein are exemplary only and they do not, to 
any extent, limit the scope or practice of the invention. 
Administration of 2-amino-1,1,3-tricyano-1-propene 
to a host, a mammal, for example, a mouse, or a rabbit, 
potentiates the effects of choline O-acetyltransferase 
and tyrosine hydroxylase. The potentiation of the ef. 
fects of choline-O-acetyltransferase is demonstrated as 
follows: 
Rat adrenal pheochromocytoma (PC-12) cells 
(1x105 per well) are plated on collagen treated 24 well 
plates (Costar) in dilutions of nerve growth factor, 2 
amino-1,1,3-tricyano-1-propene, 2-amino-1,1,3- 
tricyano-1-propene and nerve growth factor, and media 
without additives for 4 days, and choline-O-acetyl 
transferase activity is measured by the method of B. K. 
Schrier and L. Shuster, J. Neurochem., 14,977 (1967). 
Briefly, after incubation media is removed from the 
plated cells and the wells are washed three times with 
phosphate buffer. Cells are lysed with a solution of 
triton X-100 and luci of C-acetyl coenzyme is added 
to each well. The plates are then incubated at 37 C. for 
1 hour and stopped with the addition to each well of 1 
ml of cold water. The fluid in each well is poured over 
an anion exchange column, the effluent is counted by 
addition of Scinti-Verse E, and the activity is deter 
mined by measuring radioactivity on a scintillation 
counter. 
RESULTS 
Rate of Formation 
Compound Conc of Acetylcholine 
2-amino-1,1,3-tricyano- 132 pg/ml. 11.8 - 1.6 pmol/hr/ug of 
1-propene total protein 
Control 7.4 - 0.64 pmol/hr/ug of 
total protein 
The potentiation of the effects of tyrosine hydroxy 






Rat adrenal pheochromocytoma (PC-12) cells 
(1x 106 cells) are plated in collagen treated 60 mm petri 
dishes in dilutions of nerve growth factor, 2-amino 
1,1,3-tricyano-1-propene, nerve growth factor plus 2 
amino-1,1,3-tricyano-1-propene, and media without 
additives, and incubated at 37 C. for 1 hour. Tyrosine 
hydroxylase activity is measured by the method of 
Nagatsu, et al., Analyt, Biochem., 9, 122 (1964) with 
minor modifications. Briefly, after incubation, the plates 
are washed three times in phosphate buffer, scraped into 
400 ul of tris acetate buffer, and frozen until assayed. 
For the assay, the cells are thawed, homogenized, and 
centrifuged. Supernatant (50 ul) is assayed for tyrosine 
hydroxylase activity by addition of 0.5 uCi of 3H-tyro 
sine in 50 ul of buffer, and incubation of the mixture at 
37 C. for thirty minutes. The reaction is terminated by 
addition of 200 ul of acetic acid, and activity is deter 
mined by scintillation counting of tritiated water con 
tained in the effluent of the sample after treatment on an 
anion exchange column. 
RESULTS 
Conc Rate of Formation of 3H2O 
132 pg/ml. 12.78 + 0.97 fmol/hr/ug 
of total protein 
6.25 + 0.68 fmol/hr/ug 





Choline O-acetyltransferase and tyrosine hydroxy 
lase potentiation is achieved when the compound is 
administered to a subject requiring such treatment as an 
effective oral, parenteral, intracerebral, or intravenous 
dose of from about 15 to about 45 g/kg of body weight 
per day. A particularly prefered effective amount is 
about 20 vg/kg of body weight per day. It is to be 
understood, however, that for any particular subject, 
5 specific dosage regimens should be adjusted to the indi 
65 
vidual need and the professional judgment of the person 
administering or supervising the administration of the 
aforesaid compounds. It is to be further understood that 
the dosages set forth herein are exemplary only and 
they do not, to any extent, limit the scope or practice of 
the invention. 
Effective amounts of the compound and composi 
tions may be administered to a subject by any one of 
various methods, for example, orally as in capsules or 
tablets, or intracerebrally, intravenously, or parenter 
ally in the form of sterile solutions. The compound or 
compositions, while effective themselves, may be for 
mulated and administered in the form of their pharma 
5,194,426 
5 
ceutically acceptable addition salts for purposes of sta 
bility, convenience of crystallization, increased solubil 
ity and the like. 
The compound and compositions may be adminis 
tered orally, for example, with an inert diluent or with 
an edible carrier. They may be enclosed in gelatin cap 
sules or compressed into tablets. For the purpose of oral 
: therapeutic administration, the aforesaid compound and 
compositions may be incorporated with excipients and 
used in the form of tablets, troches, capsules, elixirs, 
suspensions, syrups, wafers, chewing gums, and the like. 
These preparations should contain at least 0.5% of ac 
tive compound, but may be varied depending upon the 
particular form and may convenienctly be between 
4.0% to about 70% of the weight of the unit. The 
amount of compound and compositions in such compo 
sition is such that a suitable dosage will be obtained. 
Prefered compositions and preparations according to 
the present invention are prepared so that an oral dos 
age unit form contains between 1.0-300 mgs of active 
compound. 
The tablets, pills, capsules, troches and the like may 
also contain the following ingredients: a binder such as 
microcrystalline cellulose, gum tragacanth or gelatin; 
and excipient such as starch or lactose, a disintegrating 
agent such as alginic acid, Primogel, corn starch and the 
like; a lubricant such as magnesium stearate or Sterotes; 
a glidant such as colloidal silicon dioxide; and a sweet 
ening agent such as sucrose or saccharin or a flavoring 
agent such as peppermint, methyl salicylate, or orange 
flavoring may be added. When the dosage unit form is 
a capsule it may contain, in addition to materials of the 
above type, a liquid carrier such as a fatty oil. Other 
dosage unit forms may contain other various materials 
which modify the physical form of the dosage unit, for 
example, as coatings. Thus tablets or pills may be costed 
with sugar, shellac, or other enteric coating agents. A 
syrup may contain, in addition to the active compound 
or compositions, sucrose as a sweetening agent and 
certain preservatives, dyes, colorings, and flavors. Ma 
terials used in preparing these various compositions 
should be pharmaceutically pure and non-toxic in the 
amounts used. - 
For the purpose of parenteral, intravenous, or intra 
cerebral therapeutic administration, compound and 
compositions may be incorporated into a solution or 
suspension. These preparations should contain at least 
0.1% of the aforesaid compound or compositions, but 
may be varied between 0.5% and about 50% of the 
weight thereof. The amount of active compound or 
composition in such compositions is such that a suitable 












preparations according to the present invention are 
prepared so that a parenteral, intravenous, or intracere 
bral dosage unit contains between 0.5 to 100 mgs of the 
active compound or composition. 
The solutions or suspensions may also include the 
following components: a sterile diluent such as water 
for injection, saline. solution, fixed oils, polyethylene 
glycols, glycerine, propylene glycol or other synthetic 
solvents; antibacterial agents such as benzyl alcohol or 
methyl parabens; antioxidants such as ascorbic acid or 
sodium bisulfite; chelating agents such as ethylenedi 
aminetetraacetic acid; buffers such as acetates, citrates 
or phosphates and agents for the adjustment of tonicity 
such as sodium chloride or dextrose. The parenteral, 
intravenous, or intracerebral preparation can be en 
closed in ampoules, disposable syringes or multiple dose 
vials made of glass or plastic. 
We claim: 
1. A method of inducing nerve growth in a host re 
quiring nerve growth induction comprising administer 
ing a nerve growth inducing effective amount of a com 
position consisting essentially of nerve growth factor 
and 2-amino-1,1,3-tricyano-1-propene. 
2. A method according to claim 1 wherein the effec 
tive amount of the composition is between about 15 
ug/kg of body weight and about 45 ug/kg of body 
weight. 
3. The method according to claim 2 wherein the 
effective amount of the compound is about 20 g/kg of 
body weight. 
4. A method according to claim 1 wherein the nerve 
is part of the central nervous system. 
5. A method according to claim 1 wherein the nerve 
is part of the peripheral nervous system. 
6. A method according to claim 1 wherein the nerve 
is part of the autonomic nervous system. 
7. The method according to claim 4 wherein the 
nerve of the central nervous system is selected from the 
group consisting of cholinergic and adrenergic nerves. 
8. The method according to claim 5 wherein the 
nerve of the peripheral nervous system is selected from 
the group consisting of the sciatic, ulnar, radial, and 
median nerves. 
9. The method according to claim 6 wherein the 
nerve of the autonomic nervous system is selected from 
the group consisting of the vagus, facial, glosso-pharyn 
geal, and splanchnic nerves. 
10. The method according to claim 1 wherein nerve 
growth refers to the bulk of the nerve. 
11. The method according to claim 1 wherein nerve 
growth refers to the extension of the nerve. 
